Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are currently taking daratumumab (either alone or combined with other study treatments) or other study treatments in a qualifying Janssen research study for multiple myeloma or smoldering multiple myeloma, where that study has reached its final analysis stage, and who are still benefiting from the treatment
- People who have not had their disease get worse, have not had unmanageable side effects, and have received their last dose of study treatment within the past 3 months
- People whose doctor believes the benefits of continuing the study treatment outweigh the risks
- Women who could become pregnant must have a negative pregnancy test at the start of the study and agree to further pregnancy tests during the study
- Men must agree not to donate sperm for reproduction during the study and for at least 3 months after the last dose of study treatment
- People who have signed a consent form (or had their legal representative sign) showing they understand the study and are willing to take part
- People who are willing and able to follow the lifestyle requirements set out in the study plan
Who may not be able to join:
- People who received any treatments not allowed by the study, or treatments for their disease, between finishing the original (parent) study and the planned start of study treatment
- People with any condition that, in the treating doctor's opinion, would make participation unsafe or not in their best interest, or that could interfere with the study assessments
- People with known allergies or sensitivities to any of the study treatments or their ingredients, including daratumumab, dexamethasone, carfilzomib, pomalidomide, or lenalidomide
- People who received a non-COVID-19 investigational vaccine, or a live or replicating viral vaccine, within 4 weeks before enrolling in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Serious Adverse Events (SAEs); Number of Participants with AEs of Special Interest (AESI); Number of Participants with Pregnancies or Partner Pregnancies; Number of Participants with Abnormal Pregnancies as SAE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.